作者
George G Zhanel, Christopher D Lawson, Heather Adam, Frank Schweizer, Sheryl Zelenitsky, Philippe RS Lagacé-Wiens, Andrew Denisuik, Ethan Rubinstein, Alfred S Gin, Daryl J Hoban, Joseph P Lynch, James A Karlowsky
发表日期
2013/2
来源
Drugs
卷号
73
页码范围
159-177
出版商
Springer International Publishing AG
简介
Avibactam (formerly NXL104, AVE1330A) is a synthetic non-β-lactam, β-lactamase inhibitor that inhibits the activities of Ambler class A and C β-lactamases and some Ambler class D enzymes. This review summarizes the existing data published for ceftazidime-avibactam, including relevant chemistry, mechanisms of action and resistance, microbiology, pharmacokinetics, pharmacodynamics, and efficacy and safety data from animal and human trials. Although not a β-lactam, the chemical structure of avibactam closely resembles portions of the cephem bicyclic ring system, and avibactam has been shown to bond covalently to β-lactamases. Very little is known about the potential for avibactam to select for resistance. The addition of avibactam greatly (4-1024-fold minimum inhibitory concentration [MIC] reduction) improves the activity of ceftazidime versus most species of Enterobacteriaceae depending on the …
引用总数
201320142015201620172018201920202021202220232024142547665453404046523424